Team:BostonU/Methodology

From 2012.igem.org

(Difference between revisions)
Line 218: Line 218:
<br><br>
<br><br>
<p dir="ltr">
<p dir="ltr">
-
We encoded our L1 parts library in Eugene (a computer language for synthetic biology) and generated a list of all the possible L2 parts, which are more complex genetic circuits formed by multiple transcriptional units. We selected some of them according to rules created in Eugene and proceeded to ligate an L2 DV and the chosen L1 MoClo parts in one single reaction. For further information in Eugene, refer to the “Eugene” section. Then, we performed blue-white screening, selecting white colonies and verifying sequences of the L2 MoClo parts.
+
We encoded our L1 parts library in Eugene (a computer language for synthetic biology) and generated a list of all the possible L2 parts, which are more complex genetic circuits formed by multiple transcriptional units. We selected some of them according to rules created in Eugene and proceeded to ligate an L2 DV and the chosen L1 MoClo parts in one single reaction. For further information in Eugene, refer to the <a href="https://2012.igem.org/Team:BostonU/Clotho#eugntro> Eugene</a>section. Then, we performed blue-white screening, selecting white colonies and verifying sequences of the L2 MoClo parts.
</h7>
</h7>
</ul>
</ul>

Revision as of 17:29, 26 October 2012

BostonU iGEM Team: Welcome


Methodology



Making Destination Vectors and MoClo Parts

    Building Destination Vectors

      In order to generate MoClo Destination Vectors (DV)s, we had to add the alpha fragment of lacZ to BioBrick backbones where DNA parts are normally inserted. First, we PCR amplified the alpha lacZ fragment with primers designed to add both the MoClo fusion sites and type IIs restriction sites to it.

      The amplified products and the backbones were digested with SpeI and ligated together to generate the Destination Vectors (DV)s. We performed blue-white screening to select the correct DVs and selected the blue colonies for mini preps. These were sent for sequencing to verify the correct orientation of the MoClo sites and type IIS restriction sites.



      Level 0 DVs contain Chloramphenicol resistance on the backbone (BioBrick backbone used: pSB1C3) and a BsaI site followed by a Bpil site. Level 1 DVs contain Kanamycin resistance on the backbone (BioBrick backbone used: pSB1K3) and a Bpil site followed by a BsaI site. Level 2 DVs contain Ampicillin resistance on the backbone (BioBrick backbone used: pSB1A3) and a BsaI site followed by a Bpil site.